How Ameve Sharma Is Rewriting Ayurveda’s Playbook With Kapiva
India’s $40 Bn pharma market still treats ayurveda as a side act. Ameve Sharma saw that gap early—and built Kapiva to close it with science, scale, and digital-first execution.
Founded in 2016, Kapiva clocked INR 342 Cr revenue in FY25. It now targets INR 600 Cr this fiscal, with losses narrowing to single digits. A bold ambition in a category long dismissed as slow, opaque, and unscalable.
The Market Gap: Culture Without Conviction
China turned traditional medicines into a $50 Bn mainstream pharma opportunity. India didn’t. Why?
- Ayurveda holds just 25% of India’s pharma market.
- Younger consumers want fast results, not prolonged regimens.
- Concerns around heavy metals and weak clinical validation persist.
So why hasn’t a civilisation steeped in ayurveda trusted it like China trusts TCM?
Sharma’s answer was blunt: India lacked modern, evidence-backed ayurvedic brands that could win trust beyond tradition.
A Familiar Legacy, A Radical Leap
Ayurveda wasn’t foreign to Sharma. He grew up around Baidyanath, one of India’s oldest traditional medicine brands. Yet, legacy came with limits.
After stints at McKinsey and global exposure to hyper-scaled startups, Sharma realised something crucial: innovation doesn’t thrive inside rigid family structures.
Along with Shrey Badhani, he chose the harder road—starting fresh.
“Ayurveda had to be rebuilt with startup agility,” Sharma recalled.
Kapiva was born—bootstrapped, science-led, and unapologetically D2C.
Early Stumbles, Clear Diagnosis
Kapiva’s first two years were slow. Contract manufacturing, diabetes and heart supplements, modest traction.
Instead of chasing growth, the founders fixed fundamentals:
- High-quality raw material sourcing
- Standardisation, a chronic ayurveda bottleneck
They even experimented with offline ayurvedic clinics in Mumbai after raising INR 4.4 Cr from angels. The verdict? Capital-heavy. Limited reach. Poor branding leverage.
The pivot was inevitable.
The D2C Pivot That Changed Everything
By 2018, Kapiva shut its clinics and went online-first.
Timing helped. India’s D2C market was exploding into a $100 Bn opportunity, powered by 427 Mn ecommerce users and 294 Mn active shoppers.
Digital wasn’t just distribution. It was education at scale.
Could ayurveda win trust through screens instead of shelves? Kapiva bet yes.
R&D As The Real Moat
In a crowded ayurveda landscape, Sharma chose a non-negotiable differentiator: product efficacy.
Between 2019–21, Kapiva:
- Built a 15–20 member R&D team
- Ran in vitro and in vivo studies
- Introduced clinical trials—rare in ayurveda
The inflection came in 2022. A $28 Mn Series C from OrbiMed unlocked global healthcare expertise. Practices like DNA fingerprinting and multi-layer testing followed.
Today, Kapiva products undergo up to 10 levels of testing. Certifications aren’t footnotes—they’re printed on packaging.
Would consumers pay a premium for proof? Kapiva’s repeat rates answered that.
Repeat Consumption Drives Scale
Since FY23, Kapiva’s revenues have nearly doubled every year.
- 40–65% of revenue comes from repeat customers
- Users buy a single product up to eight times a year
- Average order value: INR 1,000
Nearly 90% of revenue still flows from core categories—heart health, diabetes care, and gym supplements—despite expansions into skincare and weight management.
Ayurveda, it turns out, behaves like FMCG when trust is earned.
Distribution, Content, And Offline Resurgence
Kapiva’s revenue mix reflects omnichannel maturity:
- 35% from its own website
- 40% from online marketplaces, including quick commerce
- 25% from offline retail
Interestingly, offline department stores are now the fastest-growing channel.
Education fuels it all. Content-led marketing pushed spends from INR 17 Cr in FY21 to INR 188 Cr in FY25. On supply, contract farming ensures consistent, high-quality herbs.
Like a fitness routine, consistency—not hacks—delivered results.
Capital, Confidence, And The Road Ahead
Kapiva has raised nearly $120 Mn from investors including Fireside Ventures, 3one4 Capital, 360 One Asset, and Vertex Ventures.
A $60 Mn Series D last year is sharpening manufacturing, R&D, and brand muscle. Internationally, Kapiva already exports to the US and UK, with Germany next.
The global ayurveda market, growing 19.72% annually, is projected to hit $85.83 Bn by 2033. Kapiva wants in.
An IPO is planned within two to three years.
Building An Ecosystem, Not A Monopoly
India’s Ayush economy now exceeds $50 Bn, backed by policy support from the Ministry of Ayush.
Sharma isn’t guarding the gates. Kapiva has launched a INR 50 Cr fund to back new ayurveda entrepreneurs.
“For wider adoption, we need more players. We need to grow together.”
In a category built on balance, that may be the most ayurvedic strategy of all.
TL;DR
Kapiva, founded by Ameve Sharma, is modernising ayurveda with science-led R&D and a D2C-first model. With INR 342 Cr FY25 revenue, strong repeat rates, and global ambitions, it’s proving trust—not tradition—drives scale.
AI Summary
- IPO planned in 2–3 years
- Ayurveda underpenetrated despite cultural roots
- Kapiva built on science, clinical validation, and D2C scale
- INR 342 Cr FY25 revenue; INR 600 Cr target
- 40–65% revenue from repeat users
